Full-Time

Specialty Care Representative

Allergy and Respiratory, Cardiology and Gastroenterology

Posted on 8/18/2026

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Remote in Australia

Remote

Territory-based role covering South Australia and Tasmania; regular sales calls are required.

Bachelor's

Category
Sales & Account Management (1)

Get referred to Viatris

See people who can refer or advise you

Requirements
  • A minimum of a bachelor's degree is required; Pharmacy, Science, or Nursing is preferred.
  • A strong track record of sales success is required.
  • Hospital Sales Representative experience is required.
  • High-performing general-practice representatives should have at least five years of experience and specialty-care sales included in their development plans.
  • Experience in Allergy and Respiratory, Cardiology, and Gastroenterology is favorable.
  • Experience in the Australian pharmaceutical industry is required.
  • The candidate must be comfortable with and able to effectively persuade, negotiate, and influence.
  • The candidate must be eligible to work in Australia as an Australian citizen or appropriate visa holder.
Responsibilities
  • Engage with Allergy and Respiratory, Cardiology, and Gastroenterology specialties and allied health professionals.
  • Ensure prescribers and allied health professionals are educated, informed, and supported on relevant Viatris products.
  • Undertake regular sales calls within the assigned territory.
  • Establish and maintain relationships with key opinion leaders, prescribers, allied health professionals, and individual accounts.
  • Optimize opportunities with each account.
  • Deliver reach and frequency call goals and business development activities.
  • Deliver budgeted revenue from sales.
  • Accurately maintain all aspects of Veeva Customer Relationship Management.
Desired Qualifications
  • Experience in Allergy and Respiratory, Cardiology, and Gastroenterology is favorable.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $3.76 billion, and management raised full-year guidance.
  • Gross leverage fell to 2.9x after repaying roughly $900 million debt.
  • Fast-acting meloxicam has a December 27, 2026 FDA action date, supporting pipeline value.

What critics are saying

  • Tyvarya rights sale to Harrow shrinks growth assets and signals portfolio pruning.
  • Merck sitagliptin litigation still threatens U.S. generic launches through 2026 appeals.
  • EpiPen settlements keep Mylan-era pricing conduct alive, risking future antitrust liabilities.

What makes Viatris unique

  • Viatris spans branded, generic, and biosimilar medicines across 165 countries.
  • Greater China delivered 21% Q2 2026 growth through established brands and e-commerce.
  • FDA-approved Gwyn Lo and meloxicam add near-term proprietary launches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Aug 13th, 2026
Viatris delivers $3.8B revenue with 3.5% growth, raises outlook after strong Q2 2026

Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.

Yahoo Finance
Aug 11th, 2026
Viatris beats Q2 estimates with $3.76B revenue, ups full-year guidance amid China growth and margin pressures

Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.

PR Newswire
Aug 6th, 2026
Viatris reports Q2 revenues of $3.8B, up 5%, raises 2026 guidance despite $119M loss

Viatris reported second-quarter 2026 revenues of $3.8 billion, representing 5% reported growth compared to the same period in 2025. The pharmaceutical company posted a US GAAP net loss of $119 million, primarily driven by a non-cash charge of $177.8 million related to the planned sale of Tyrvaya product rights. Adjusted EBITDA reached $1.2 billion, up 8% operationally year-over-year. The company returned approximately $550 million to shareholders, including roughly $270 million through share repurchases at a weighted average price of $16.42 per share. Viatris reduced its gross leverage ratio to 2.9x after repaying approximately $900 million in debt. The company raised its full-year 2026 financial guidance midpoints across all metrics. In July, Viatris received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch expected to launch later this year.

Yahoo Finance
Aug 2nd, 2026
Viatris wins FDA approval for Gwyn Lo contraceptive patch

Viatris has received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch. The product adds a new branded option to the company's women's health portfolio. Gwyn Lo's approval comes as Viatris shares have shown strong momentum. The stock currently trades at $17.56, reflecting a 40.9% year-to-date return and 107.2% gain over the past year. The contraceptive patch may help diversify Viatris' revenue mix. Investors will be watching how quickly the product gains traction in prescribing patterns and market share. The company's shares trade close to the analyst price target of $17.94. However, Viatris carries a high forward price-to-earnings ratio of 57.84, and its 2.73% dividend yield is reportedly not well covered by earnings.

TipRanks
Jul 1st, 2026
Viatris secures $260M term loan facility to refinance debt and support operations

Viatris has secured a ¥40 billion (approximately $270 million) unsecured term loan facility with a syndicate of lenders led by Mizuho Bank. The three-year facility, which closed on 1 July 2026, will support general corporate purposes and refinance a prior loan of the same amount. The facility is priced at the TIBO Rate plus 1.10%, with pricing linked to Viatris' long-term credit ratings. It includes leverage ratio limits, standard covenants on indebtedness, dividends and mergers, plus default provisions allowing lenders to accelerate repayment. The loan is backed by guarantees from key Viatris subsidiaries and allows penalty-free prepayments, providing the pharmaceutical company with liquidity in the Japanese market whilst maintaining financial flexibility.